FDA accepts to review Sanofi’s multiple myeloma candidate isatuximab

This article was originally published here

An investigational monoclonal antibody, isatuximab, has been designed to target a specific epitope on the CD38 receptor of a plasma cell. The drug has been designed to activate

The post FDA accepts to review Sanofi’s multiple myeloma candidate isatuximab appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply